Clinical trials: Persistent Corneal Epithelial Defects
Dry Eyes, Sjogren's Disease With Dry Eyes
Treating Dry Eyes and Corneal Ulcers With Fingerprick Autologous Blood
To investigate if fresh finger prick autologous blood (FAB) instead of serum from venesection, is a safe and effective treatment for dry eyes and corneal ulcers/ epithelial defects.
- Conditions
- Dry Eyes, Sjogren's Disease With Dry Eyes, Persistent Corneal Epithelial Defects, Chronic Corneal Ulcers
- Trial name
- FAB (NCT02153515)
- Testing
- Your own ( autologous) finger prick of blood produced with a diabetic lancet
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Bedford Hospital NHS Trust
Persistent Corneal Epithelial Defects, Dry Eye
Platelet Rich Plasma in Corneal Surface Diseases
The Aim of the study is to evaluate the efficacy of platelet rich plasma eye drops in the management of different corneal surface disorders.
- Trial name
- NCT05320172
- Testing
- Autologous platelet rich plasma eye drops
- Volunteers
- 70 people
- Sponsor
- Assiut University
Persistent Corneal Epithelial Defect
A Study to Evaluate the Efficacy and Safety of TP-06 for PCED
Capellion is a Phase 2 trial comparing TP-06 2.0% with Vehicle in up to 32 adults with persistent corneal epithelial defects. Participants will receive treatment for 8 weeks and be followed for 2 additional weeks to assess…
- Trial name
- Capellion (NCT07886268)
- Testing
- TP-06, Vehicle of TP-06
- Where
- 14 sites in United States, Dominican Republic and 2 more
- Volunteers
- 32 people
- Sponsor
- Tarsus Pharmaceuticals, Inc.
Persistent Corneal Epithelial Defect
A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial Defects
The objective of this study is to evaluate the safety and effectiveness of topical KIO-201 in patients with persistent corneal epithelial defects (PED). KIO-201 will be administered six (6) times per day while awake for 4 weeks.
- Trial name
- NCT05436288
- Testing
- KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S)
- Where
- Mexico
- Volunteers
- 10 people
- Sponsor
- Kiora Pharmaceuticals, Inc.
Persistent Corneal Epithelial Defect
Comparison of Topical Insulin and Amniotic Membrane Transplant for Persistent Corneal Epithelial Defects
After an initial period of standard treatment, they received further care aimed at helping the surface of the eye heal. Clear instructions were given on how to use and store the treatment properly.
- Trial name
- NCT07561398
- Testing
- Topical insulin eye drops, Amniotic Membrane Graft
- Where
- Pakistan
- Volunteers
- 214 people, healthy volunteers welcome
- Sponsor
- Al-Shifa Trust Eye Hospital
Persistent Corneal Epithelial Defect
ST266 Eyedrops for the Treatment of Persistent Corneal Epithelial Defects
The primary objective is to determine the efficacy of ST266 eye drops in healing persistent epithelial defects (PED). After 8 weeks of randomized, double-blind treatment, non-healers will enter into an additional 8-week…
- Trial name
- NCT05066698
- Testing
- ST266, 0.67% Sodium Chloride Ophthalmic Solution, Open-label ST266
- Where
- 31 sites in United States
- Volunteers
- 8 people
- Sponsor
- Noveome Biotherapeutics, formerly Stemnion
Persistent Corneal Epithelial Defects
Efficacy and Safety Study of Nexagon for Persistent Corneal Epithelial Defects
The purpose of this study is to evaluate the efficacy and safety of Nexagon® in subjects with persistent corneal epithelial defects (PED) resulting from corneal epithelial debridement during diabetic vitrectomy surgery, HSV…
- Trial name
- NTX-PED-001 (NCT01165450)
- Testing
- Nexagon, Vehicle only
- Volunteers
- 2 people
- Sponsor
- University of California, San Francisco
Persistent Epithelial Defect
A Study to Investigate the Safety and Clinical Effect of Nexagon® to Treat Persistent Epithelial Defects
The purpose of this study is to evaluate the efficacy and safety of Nexagon® in subjects with Persistent Epithelial Defects (PED) originally caused by chemical burns.
- Trial name
- NCT00821561
- Testing
- Nexagon®, Nexagon® vehicle
- Volunteers
- 90 people
- Sponsor
- OcuNexus Therapeutics, Inc.
Corneal Persistent Epithelial Defect
NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Injuries
This study will enroll participants with a non-infected, corneal persistent epithelial defect (PED) resulting from an ocular chemical and/or thermal ocular injury which is non-responsive or refractory to current standard of care…
- Trial name
- EXPEDE (NCT04081103)
- Testing
- Nexagon® (lufepirsen) High Dose Concentration, Nexagon® (lufepirsen) Low Dose Concentration, Vehicle
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Glaukos Corporation
Persistent Corneal Epithelial Defect
A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED
This study is to evaluate the safety and efficacy of NEXAGON® (lufepirsen ophthalmic gel) (NEXAGON) in subjects with persistent corneal epithelial defects (PCED).
- Trial name
- NEXPEDE-1 (NCT05966493)
- Testing
- lufepirsen high dose, Vehicle, lufepirsen low dose
- Where
- 28 sites in United States, Germany and 2 more
- Volunteers
- 84 people
- Sponsor
- Glaukos Corporation
Corneal Diseases
Autologous Serum Eye Drops With Contact Lenses for Corneal Epithelial Defects
To evaluate the clinical effect of combination of topical 20% (v/v) autologous serum eye drops and a silicone-hydrogel contact lens (CLs) in the treatment of recalcitrant persistent epithelial defects (PEDs) and the recurrence…
- Trial name
- NCT02291731
- Testing
- Continuous use of topical autologous serum
- Where
- Taiwan
- Volunteers
- 21 people
- Sponsor
- E-DA Hospital
Cornea
Healing of Persistent Epithelial Defects
The purpose of this study is to compare the relative efficacy of four different treatment modalities (i.e. aggressive lubrication, bandage contact lens, Ambiodisk amniotic membrane, Prokera amniotic membrane) in the healing of…
- Trial name
- NCT02395952
- Testing
- carboxymethylcellulose sodium, Acuvue Oasys Bandage Contact Lens, Ambiodisk
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Persistent Corneal Epithelial Defect
Autologous Platelet Lysate in Corneal Epithelial Defects
Patients diagnosed with persistent corneal epithelial ulcers will be treated with autologous platelet lysate.
- Trial name
- NCT02979912
- Testing
- Platelet Lysate
- Where
- Jordan
- Volunteers
- 10 people
- Sponsor
- Hanan Jafar
Persistent Corneal Epithelial Defect, Corneal Epithelial Disorders
Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease
In this phase II randomized double-masked clinical trials, subjects with non-resolving corneal epithelial disease/defect (i.e., refractory to standard treatments for at least two weeks) will receive 8 weeks treatment of topical…
- Trial name
- NCT06919081
- Testing
- Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome, Vehicle Control
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Illinois Chicago
Persistent Epithelial Defect
Autologous Platelet-rich Plasma in the Treatment of Persistent Epithelial Defects
Persistent epithelial defects (PED) are corneal ulcers that do not heal within the first two weeks of treatment with artificial tears or ocular lubricant ointment.
- Trial name
- NCT03653650
- Testing
- PRP plus BCL, BCL plus PFL, Eye patch plus ocular lubricant ointment
- Where
- Mexico
- Volunteers
- 54 people
- Sponsor
- Universidad Autonoma de Nuevo Leon
Persistent Corneal Epithelial Defect
ST266 Eye Drops for the Treatment of Persistent Corneal Epithelial Defects
The primary aim of the study is to evaluate the clinical response of ST266 treated subjects with persistent corneal epithelial defects during 28 days of therapy.
- Trial name
- NCT03687632
- Testing
- ST266
- Where
- 8 sites in United States
- Volunteers
- 13 people
- Sponsor
- Noveome Biotherapeutics, formerly Stemnion
Corneal Epithelial Defect
Treatment of PED With AMT and Autologous Serum
Patients with persistent corneal epithelial defects who have not responded to conventional therapy will be randomized to treatment with either amniotic membrane transplantation or autologous serum 20%.
- Trial name
- NCT00238862
- Testing
- Amniotic membrane transplantation, Autologous serum/BSS 20%
- Where
- Saudi Arabia
- Volunteers
- 180 people
- Sponsor
- King Khaled Eye Specialist Hospital